FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 592 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone... July 29, 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel June 28, 2021 ESMO Award for Immuno-Oncology 2025 Recipient Announced November 4, 2025 Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not... December 9, 2021 Load more HOT NEWS FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC Tumor Signatures May Help Explain Global Differences in Kidney Cancer Rates “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can... EMA Recommends Extension of Therapeutic Indications for Acalabrutinib
